Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Weight gain associated with cinnarizine.

J Navarro-Badenes1, I Martínez-Mir, V Palop

  • 1Departament de Farmacologia, Universitat de València, Spain.

The Annals of Pharmacotherapy
|July 1, 1992
PubMed
Summary

Cinnarizine, a medication for vertigo and migraine, may cause significant weight gain in patients. This weight gain is linked to increased appetite and can be reversed upon discontinuing the drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diuretics use in the management of hypertension.

Hipertension y riesgo vascular·2024
Same author

A review of <i>Hyphodiscaceae</i>.

Studies in mycology·2023
Same author

Carriage of multidrug-resistant Gram-negative bacilli: duration and risk factors.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2023
Same author

[2022 Practice guidelines for the management of arterial hypertension of the Spanish Society of Hypertension].

Hipertension y riesgo vascular·2022
Same author

2021 Spanish Society of Hypertension position statement about telemedicine.

Hipertension y riesgo vascular·2021
Same author

Fungal Planet description sheets: 1042-1111.

Persoonia·2020

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Obesity Research

Background:

  • Cinnarizine is a piperazine derivative commonly prescribed for vertigo and migraine prophylaxis.
  • Limited clinical trial data exist for cinnarizine due to inconclusive results.

Observation:

  • Four cases of adult women (50-57 years) without metabolic issues experienced weight gain while taking cinnarizine for 1-2 years.
  • Weight gain averaged 6.25 kg and was associated with increased appetite and food intake.
  • In two cases, cinnarizine was co-administered with dihydroergocristine.

Findings:

  • Cinnarizine intake was linked to substantial weight gain, independent of initial BMI.
  • Discontinuation of cinnarizine led to weight normalization in one patient.
  • The observed weight gain is consistent with effects seen with other piperazine derivatives.

Implications:

  • Cinnarizine should be considered a potential cause of unexplained weight gain in clinical practice.
  • Further research is warranted to elucidate the mechanism of cinnarizine-induced weight gain.
  • Clinicians should monitor for weight changes in patients using cinnarizine.

Related Experiment Videos